With seizure drug held up at FDA again, Aquestive replaces longtime CEO

Max Gelman

Senior Editor

The C-suite musical chairs reverberating through biotech the last few months continued Tuesday afternoon with another small cap company announcing a transition at the top …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With seizure drug held up at FDA again, Aquestive replaces longtime CEO

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

GSK defiant against vaccine challenges, will prioritize other growth areas

Small personalized vaccine trial sees progress in late-stage kidney cancer

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

With seizure drug held up at FDA again, Aque­s­tive re­places long­time CEO

Senior Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

With seizure drug held up at FDA again, Aquestive replaces longtime CEO